Clearside Biomedical Stock Predictions

Healthcare > Biotechnology

Buy CLSD

*Your capital is at risk

$0.410

+0 (+0%)

At Close: Mar 13, 2026

Currently predicting for Mon, 8 Jun 2026

CLSD Prediction Chart

CLSD Predictions History

Latest community submissions for CLSD.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
cmcclenny	Jul 6, 2021	Bullish	$5.54	X	—	1
JS Pro	Dec 4, 2020	$2.11 -0.94%	$2.13	X	99.06%	2
JS Pro	Nov 30, 2020	$1.90 -5.47%	$2.01	X	94.53%	0
JS Pro	Nov 27, 2020	$1.90 -2.56%	$1.95	X	97.44%	1
Craig Johnson @CraigJohnson.179277	Nov 27, 2020	$3.35 +71.79%	$1.95	X	28.21%	0
JS Pro	Nov 11, 2020	$1.50 +2.74%	$1.46	X	97.26%	1
JS Pro	Aug 11, 2020	$1.81 +4.62%	$1.73	X	95.38%	0
2poJeff Pro	Aug 11, 2020	$1.78 +2.89%	$1.73	X	97.11%	0
phokhong Amateur	Aug 11, 2020	$1.73 +0.00%	$1.73	X	100.00%	10
sander7100 yo bro Pro @sander7100yobro.167552	Aug 11, 2020	$1.72 -0.58%	$1.73	X	99.42%	4

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CLSD with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT CLEARSIDE BIOMEDICAL, INC

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an i...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by